|ID:117 ||Lithium||Search Links: General Info : Protocols : Patient Info|
|Description||Drug used in treatment of depression. Therapeutic concentrations are based on samples taken >12h post dose. Routine monitoring of patients is essential. Patients should also have TFT's monitored.|
|Indication||Therapeutic Drug Monitoring.
|Additional Info||EFFECT OF LITHIUM: <0.4 mmol/L the therapeutic response is poor. Levels between 0.4 - 0.6 mmol/L may possible be beneficial for prophylaxis but the chance of relapse is high. The optimum range is between 0.6 - 0.8 mmol/L. Levels >1.2 mmol/L are associated with the risk of renal impairment. Levels between 1.5 - 3.0 are associated with renal impairment, ataxia, weakness and drowsiness. Above 3.0 mmol/L symptoms include dehydration, confusion, spasticity, seizures and coma.|
|Interpretation||Ideally levels want to be within the target range.
|Ref. Range (Male)||0.4 - 1.0|
|Ref. Range (Female)||0.4 - 1.0|
|Ref. Range (Paed)|| |
|Ref. Range Notes|
|IP Acute TAT||Refer to Website|
|IP Routine TAT||Refer to Website|
|GP Acute TAT||- Contact Laboratory|
|GP Routine TAT||Refer to Website|
Originally edited by : JHB. Last edited on 21/06/2017 12:03:46. Published By S.BENNETT on 21/06/2016 12:03:46.